TY - JOUR
T1 - Heat shock transcription factor 1 is a key determinant of HCC development by regulating hepatic steatosis and metabolic syndrome
AU - Jin, Xiongjie
AU - Moskophidis, Demetrius
AU - Mivechi, Nahid F.
N1 - Funding Information:
The research was supported by National Institutes of Health grants CA062130 and CA132640 (N.F.M.) and CA121951 (D.M.).
PY - 2011/7/6
Y1 - 2011/7/6
N2 - Hepatocellular carcinoma (HCC) occurrence and progression are linked tightly to progressive hepatic metabolic syndrome associated with insulin resistance, hepatic steatosis, and chronic inflammation. Heat shock transcription factor 1 (HSF1), a major transactivator of stress proteins, increases survival by protecting cells against environmental stressors. It has been implicated in the pathogenesis of cancer, but specific mechanisms by which HSF1 supports cancer development remain elusive. We propose a pathogenic mechanism whereby HSF1 activation promotes growth of premalignant cells and HCC development by stimulating lipid biosynthesis and perpetuating chronic hepatic metabolic disease induced by carcinogens. Our work shows that inactivation of HSF1 impairs cancer progression, mitigating adverse effects of carcinogens on hepatic metabolism by enhancing insulin sensitivity and sensitizing activation of AMP-activated protein kinase (AMPK), an important regulator of energy homeostasis and inhibitor of lipid synthesis. HSF1 is a potential target for the control of hepatic steatosis, hepatic insulin resistance, and HCC development.
AB - Hepatocellular carcinoma (HCC) occurrence and progression are linked tightly to progressive hepatic metabolic syndrome associated with insulin resistance, hepatic steatosis, and chronic inflammation. Heat shock transcription factor 1 (HSF1), a major transactivator of stress proteins, increases survival by protecting cells against environmental stressors. It has been implicated in the pathogenesis of cancer, but specific mechanisms by which HSF1 supports cancer development remain elusive. We propose a pathogenic mechanism whereby HSF1 activation promotes growth of premalignant cells and HCC development by stimulating lipid biosynthesis and perpetuating chronic hepatic metabolic disease induced by carcinogens. Our work shows that inactivation of HSF1 impairs cancer progression, mitigating adverse effects of carcinogens on hepatic metabolism by enhancing insulin sensitivity and sensitizing activation of AMP-activated protein kinase (AMPK), an important regulator of energy homeostasis and inhibitor of lipid synthesis. HSF1 is a potential target for the control of hepatic steatosis, hepatic insulin resistance, and HCC development.
UR - http://www.scopus.com/inward/record.url?scp=79959947025&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959947025&partnerID=8YFLogxK
U2 - 10.1016/j.cmet.2011.03.025
DO - 10.1016/j.cmet.2011.03.025
M3 - Article
C2 - 21723507
AN - SCOPUS:79959947025
SN - 1550-4131
VL - 14
SP - 91
EP - 103
JO - Cell Metabolism
JF - Cell Metabolism
IS - 1
ER -